Antibody therapeutics companies develop engineered antibodies that target specific molecules involved in disease. These medicines are used across oncology, autoimmune disease, inflammatory conditions, infectious disease and other areas of clinical development.
This category includes companies working on:
Browse 69 UK antibody therapeutics companies below.
Data-driven cis-bispecific antibody-drug conjugates for solid tumour cancers
Promatix Biosciences is an oncology drug discovery company developing next-generation bispecific antibody-drug conjugates through data-driven target pairing. Using a proteomics…
Contract antibody discovery, engineering and supply services
Fusion Antibodies is a contract research organisation specialising in preclinical antibody discovery, engineering and supply for pharmaceutical and diagnostic clients. Services…
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a…
ADC pipeline targeting mutant stem cells in blood cancers
Alethio Therapeutics Limited is a preclinical-stage biotechnology company developing antibody-drug conjugates for myeloproliferative neoplasms, a group of chronic blood cancers.…
Off-the-shelf cancer immunotherapies targeting solid tumours
Scancell is a clinical-stage biotech developing active immunotherapies and antibody-based therapeutics for cancer. Its pipeline spans DNA cancer vaccines, peptide immunotherapies…
Targeted antibody therapeutics for cancer and autoimmune disease
Medannex is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics targeting annexin-A1, a protein implicated in cancer progression, autoimmunity,…
Biologic therapies for autoinflammatory and autoimmune diseases
Kiniksa Pharmaceuticals International is a commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising medicines for autoinflammatory and…
Bispecific antibody-drug conjugates for cancer-selective precision therapy
BiVictriX Therapeutics is a clinical-stage biotechnology company developing bispecific antibody-drug conjugates for cancer. The platform targets pairs of cancer-specific antigens…
Multispecific immune cell engagers targeting gamma delta T cells
Cytospire Therapeutics is developing multispecific engager antibodies designed to enhance and direct the activity of gamma delta T cells for the treatment of cancer and autoimmune…
Global CDMO for biologics development and manufacture
Lonza is one of the world's largest contract development and manufacturing organisations, providing services across biologics, cell and gene therapy, and small molecules. Its…
Oral delivery platform for biologics targeting inflammatory diseases
Intract Pharma is a biotechnology company developing proprietary formulation platforms for the oral delivery of complex biologics including monoclonal antibodies and proteins. The…
Shark-derived single-domain antibody biologics for cancer and inflammation
Elasmogen is a biotechnology company developing next-generation therapeutic biologics based on its proprietary soloMER platform, single-domain antibody-like proteins derived from…